Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06877533 · ClinicalTrials.gov registry record · Phase 1
A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors
A Phase 1 study, sponsored by iTeos Belgium.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT06877533: Clinical Trial Phase 1 study, sponsored by iTeos Belgium.
NCT06877533 is a Phase 1 study that was terminated before completion, run by iTeos Belgium. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06877533, a Phase 1 study, was terminated before completion, sponsored by iTeos Belgium.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). The study includes EOS006215 monotherapy and combination therapy with other anticancer agents in participants with advanced solid tumors.
Interventions
- DRUG EOS006215
- DRUG Anticancer agent
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2025-04-07 |
| Est. Completion | 2025-07-10 |
| Phase | Phase 1 |
Why NCT06877533 stopped before completion
NCT06877533 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which EOS006215 is the first listed.
NCT06877533 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06877533 about?
NCT06877533 is a clinical study titled "A First-in-Human Open-label, Phase I/Ib Dose Escalation and Expansion Cohort Study of EOS006215 as Monotherapy and in Combination With Pembrolizumab or Other Anticancer Treatments in Participants With Advanced Solid Tumors". TRM-010 is a first-in-human (FIH) clinical study designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of EOS006215, a fully human monoclonal antibody that binds to the triggering receptor expressed on myeloid cells 2 (TREM2). T...
What is the current status of trial NCT06877533?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2025-04-07. Estimated completion is 2025-07-10.
What interventions are being tested in trial NCT06877533?
The interventions under investigation include: EOS006215 (DRUG), Anticancer agent (DRUG).
Who is sponsoring clinical trial NCT06877533?
This trial is sponsored by iTeos Belgium, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06877533's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI